onc Videos

Videos

David Siegel, MD, PhD, Hackensack Meridian Health

Conference Coverage

Exploring the Role of Stem Cell Transplant for Patients With Myeloma Older Than 65

04/19/2024

Featuring David Siegel, MD, PhD

Featuring David Siegel, MD, PhD ...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...

At the 2024 Great Debates &...

04/19/2024

Oncology

Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey

Conference Coverage

Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma

04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.

During the 2024 Great Debates &...

04/16/2024

Oncology

Brea Lipe, University of Rochester Medical Center

Conference Coverage

Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?

04/16/2024

Featuring Brea Lipe, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.

During the 2024 Great Debates &...

04/16/2024

Oncology

Thomas Powles, MD, MBBS, Barts Cancer Institute

Videos

Enfortumab Vedotin and Pembrolizumab Among Patients With Advanced Urothelial Cancer in the First-Line Setting

04/11/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD, discusses results from the phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab improved survival outcomes among patients with previously untreated advanced urothelial carcinoma.

Thomas Powles, MBBS, MD,...

04/11/2024

Oncology

Conference Coverage

Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment

04/10/2024

Featuring John Allan, MD

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.

John Allan, MD, compares the use...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting

04/10/2024

Featuring Ashley Rosko, MD

Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...

Ashley Rosko, MD, discusses...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center

Conference Coverage

Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS

04/10/2024

Featuring Aditi Shastri, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...

During the 2024 Great Debates &...

04/10/2024

Oncology

Conference Coverage

Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?

04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...

At the 2024 Great Debates &...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Joseph Mikhael, MD, City of Hope Cancer Center

Conference Coverage

Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment

04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.

During the 2024 Great Debates &...

04/09/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy

04/09/2024

Featuring Jessica Altman, MD

During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...

During the 2024 Great Debates &...

04/09/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology